First Reports of Adverse Drug Reactions (ADRs) in Recent Weeks
First Reports of Adverse Drug Reactions (ADRs) in Recent Weeks
The following table contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks. Any claim to a 'first report' is verified by a database search of previous literature.
Serious: an event is serious (FDA MedWatch definition) when the patient outcome is death, life-threatening, hospitalisation, disability, congenital anomaly, or requires intervention to prevent permanent impairment or damage.
The following table contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks. Any claim to a 'first report' is verified by a database search of previous literature.
| Drug and ADR | Reference |
|---|---|
| Amoxicillin/clavulanic acid: neutrophilic fixed drug eruption | Agnew Kl, Oliver GF. Neutrophilic fixed drug eruption. Aust J Dermatol 2001 Aug; 42: 200-2 |
| Antiretrovirals: tendon xanthomata with highly active antiretroviral therapy (saquinavir, ritonavir, stavudine, lamivudine) | Leung N, Carpentier A, Wang J, et al. Rapid development of massive tendon xanthomata following treatment with highly active antiretroviral therapy (HAART). Diabetes 2001 Jun; 50 Suppl. 2: 452-3 |
| Celecoxib: anaphylaxis (serious) | Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001 Jul; 87: 72-3 |
| Ciprofloxacin/vancomycin: linear IgA bullous dermatosis in an elderly patient | Wiadrowski TP, Reid CM. Drug-induced linear IgA bullous disease following antibiotics. Austral J Dermatol 2001 Aug; 42: 196-9 |
| Efavirenz: gynaecomastia | Arranz Caso JA, de Miguel Prieto J, Casas E, et al. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS 2001 Jul; 15: 1447-8 |
| Mirtazapine: pancreatitis | Sommer M, Dieterich A, Krause C, et al. Subclinical pancreatitis related to mirtazapine - a case report. Pharmacopsych 2001 Jul; 34: 158-9 |
| Mycophenolate mofetil: deep vein thrombosis (serious) | Cherney DZI, Zaltzman JS. Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V leiden. Neph Dial Transp 2001 Aug; 16: 1702-4 |
| Nadroparin calcium/enoxaparin sodium: liver disorders | Hui C-K, Yuen M-F, Ng IO-L, et al. Low molecular weight heparininduced liver toxicity. J Clin Pharmacol 2001 Jun; 41: 691-4 |
| Ofloxacin: diabetes insipidus | Bharani A, Kumar H. Diabetes insipidus induced by ofloxacin. BMJ2001 Sep; 323: 547 |
| Rituximab: serum sickness (serious) | D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arth Rheum 2001 Jul; 44: 1717-8 |
| Serenoa repens: perioperative haemorrhage (serious) | Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. J Int Med 2001 Aug; 250: 167-9 |
Serious: an event is serious (FDA MedWatch definition) when the patient outcome is death, life-threatening, hospitalisation, disability, congenital anomaly, or requires intervention to prevent permanent impairment or damage.
Source...